Pouwels Koen B, Bozdemir Sefika E, Yegenoglu Selen, Celebi Solmaz, McIntosh E David, Unal Serhat, Postma Maarten J, Hacimustafaoglu Mustafa
Unit of PharmacoEpidemiology & PharmacoEconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.
Modelling & Economics Unit, Centre for Infectious Disease Surveillance & Control, Public Health England, London, United Kingdom.
PLoS One. 2016 Sep 30;11(9):e0163567. doi: 10.1371/journal.pone.0163567. eCollection 2016.
Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in various stages. To assess whether one of these vaccines might be a future asset for national immunization programs, modeling the costs and benefits of various vaccination strategies is needed.
To evaluate the potential cost-effectiveness of RSV vaccination of infants and/or pregnant women in Turkey.
A multi-cohort static Markov model with cycles of one month was used to compare the cost-effectiveness of vaccinated cohorts versus non-vaccinated cohorts. The 2014 Turkish birth cohort was divided by twelve to construct twelve monthly birth cohorts of equal size (111,459 new-borns). Model input was based on clinical data from a multicenter prospective study from Bursa, Turkey, combined with figures from the (inter)national literature and publicly available data from the Turkish Statistical Institute (TÜÏK). Incremental cost-effectiveness ratios (ICERs) were expressed in Turkish Lira (TL) per quality-adjusted life year (QALY) gained.
Vaccinating infants at 2 and 4 months of age would prevent 145,802 GP visits, 8,201 hospitalizations and 48 deaths during the first year of life, corresponding to a total gain of 1650 QALYs. The discounted ICER was estimated at 51,969 TL (26,220 US $ in 2013) per QALY gained. Vaccinating both pregnant women and infants would prevent more cases, but was less attractive from a pure economic point of view with a discounted ICER of 61,653 TL (31,106 US $ in 2013) per QALY. Vaccinating only during pregnancy would result in fewer cases prevented than infant vaccination and a less favorable ICER.
RSV vaccination of infants and/or pregnant women has the potential to be cost-effective in Turkey. Although using relatively conservative assumptions, all evaluated strategies remained slightly below the threshold of 3 times the GDP per capita.
在全球范围内,呼吸道合胞病毒(RSV)被认为是婴幼儿呼吸道疾病发病和死亡的最重要病毒病因。尽管目前市场上尚无有效的疫苗,但有几个处于不同阶段的疫苗研发项目。为了评估这些疫苗中的一种是否可能成为国家免疫规划的未来资产,需要对各种疫苗接种策略的成本和效益进行建模。
评估在土耳其对婴儿和/或孕妇接种RSV疫苗的潜在成本效益。
使用一个每月循环一次的多队列静态马尔可夫模型,比较接种疫苗队列和未接种疫苗队列的成本效益。将2014年土耳其出生队列除以12,构建12个规模相等的月度出生队列(111,459名新生儿)。模型输入基于土耳其布尔萨一项多中心前瞻性研究的临床数据,结合(国际)文献数据和土耳其统计局(TÜÏK)公开的数据。增量成本效益比(ICER)以每获得一个质量调整生命年(QALY)的土耳其里拉(TL)表示。
在婴儿2个月和4个月时接种疫苗,在生命的第一年可预防145,802次全科医生就诊、8,201次住院和48例死亡,相当于总共获得1650个QALY。估计每获得一个QALY的贴现ICER为51,969 TL(2013年为26,220美元)。对孕妇和婴儿都进行接种可预防更多病例,但从纯粹经济角度来看吸引力较小,每获得一个QALY的贴现ICER为61,653 TL(2013年为31,106美元)。仅在孕期接种疫苗预防的病例比婴儿接种少,ICER也更不理想。
在土耳其,对婴儿和/或孕妇接种RSV疫苗有可能具有成本效益。尽管使用了相对保守的假设,但所有评估策略仍略低于人均国内生产总值3倍的阈值。